NeuroBo Pharmaceuticals is addressing unmet needs in patients with neuropathic and neurodegenerative diseases by developing and commercializing multimodal disease-modifying therapies. Their drug candidates have shown promising results in preclinical and clinical studies, with NB-01 and NB-02 being the most advanced. NB-01 has shown superior efficacy and safety in treating diabetic neuropathic pain compared to currently available treatments, while NB-02 has been extensively characterized in rodent models for mechanisms impacting Alzheimer's disease. NeuroBo's portfolio also includes ANA001, a proprietary oral niclosamide formulation being studied in a Phase 2/3 clinical trial for the treatment of COVID-19.